A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)

References

Page 1

	Year	Citations
Cancer statistics, 2014 Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou, CA A Cancer Journal for Clinicians Epidemiology Of CancerCancer RegistrationUnited StatesCancer Risk FactorsGynecology Oncology	2014	11.5K
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Alan Sandler, Robert J. Gray, Michael C. Perry, New England Journal of Medicine	2006	5.8K
Two pathogenetic types of endometrial carcinoma Jan V. Bokhman Gynecologic Oncology Endocrine-related CancerEndometriosisGynecologyPathologyEndometrial Carcinoma	1983	2.5K
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert A. Burger, Mark F. Brady, Michael A. Bookman, New England Journal of Medicine	2011	2.3K
Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study Marcus E. Randall, Virginia L. Filiaci, Hyman B. Muss, Journal of Clinical Oncology	2005	866
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – Results from two randomised studies Thomas Högberg, Mauro Signorelli, Carlos Oliveira, European Journal of Cancer Sequential Adjuvant ChemotherapyRadiation TherapyMedicineGynecologyCancer Treatment	2010	448
Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy, Journal of Clinical Oncology	2011	312
Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II Study Paul Hoskins, Kenneth D. Swenerton, J.A. Pike, Journal of Clinical Oncology	2001	277
Outcome of High-Risk Stage IC, Grade 3, Compared With Stage I Endometrial Carcinoma Patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial Carien L. Creutzberg, Wim L.J. van Putten, Carla C. Wárlám-Rodenhuis, Journal of Clinical Oncology	2004	277
Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study David S. Miller, Virginia L. Filiaci, Gini F. Fleming, Gynecologic Oncology First Line ChemotherapyMedicineClinical EndpointGynecologyCancer Treatment	2012	249

Page 1